STRYKER CORPSYK
STRYKER CORP Fair Value Disclosure
FAIR VALUE MEASUREMENTS
Fair value is defined as the price that would be received to sell an
asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. Financial
assets and liabilities carried at fair value are classified in their
entirety based on the lowest level of input and disclosed in one of
the following three categories:
Level 1 | Quoted market prices in active markets for identical assets or liabilities. |
Level 2 | Observable market-based inputs or unobservable inputs that are corroborated by market data. |
Level 3 | Unobservable inputs reflecting our assumptions or external inputs from active markets. |
Use of observable market data, when available, is required in
making fair value measurements. When inputs used fall within
different levels of the hierarchy, the level within which the fair
value measurement is categorized is based on the lowest level
input that is significant to the fair value measurement. We
determine fair value for Level 1 instruments using exchange-
traded prices for identical instruments. We determine fair value of
Level 2 instruments using exchange-traded prices of similar
instruments, where available, or utilizing other observable inputs
that take into account our credit risk and that of our
counterparties. Foreign currency exchange contracts and interest
rate hedges, when outstanding, are included in Level 2 and are
primarily valued using standard calculations and models that use
readily observable market data as their basis. Our Level 3
liabilities comprise contingent consideration arising from recently
completed acquisitions. We determine fair value of these Level 3
liabilities using a discounted cash flow technique. Significant
unobservable inputs were used in our assessment of fair value,
including assumptions regarding future business results, discount
rates, discount periods and probability assessments based on the
likelihood of reaching various targets. We remeasure the fair
value of our assets and liabilities each reporting period. We
record the changes in fair value within selling, general and
administrative expense.
In 2025 we assumed contingent consideration liabilities with a fair
value of $90 related to previous acquisitions made by Inari
Medical Inc. (Inari). Refer to Note 6 for further information on the
acquisition of Inari.
In 2024 we recorded $208 of contingent consideration related to
various acquisitions described in Note 6.
There were no significant transfers into or out of any level of the
fair value hierarchy in 2025.
Assets Measured at Fair Value | |||
2025 | 2024 | ||
Cash and cash equivalents | $4,011 | $3,652 | |
Short-term investments | — | 750 | |
Trading marketable securities | 307 | 259 | |
Level 1 - Assets | $4,318 | $4,661 | |
Available-for-sale marketable securities: | |||
Corporate and asset-backed debt securities | $52 | $53 | |
United States agency debt securities | — | 1 | |
United States treasury debt securities | 37 | 34 | |
Certificates of deposit | — | 3 | |
Total available-for-sale marketable securities | $89 | $91 | |
Foreign currency exchange forward contracts | 46 | 225 | |
Level 2 - Assets | $135 | $316 | |
Total assets measured at fair value | $4,453 | $4,977 | |
Liabilities Measured at Fair Value | |||
2025 | 2024 | ||
Deferred compensation arrangements | $307 | $259 | |
Level 1 - Liabilities | $307 | $259 | |
Foreign currency exchange forward contracts | $170 | $77 | |
Level 2 - Liabilities | $170 | $77 | |
Contingent consideration: | |||
Beginning | $452 | $289 | |
Additions | 123 | 208 | |
Change in estimate and foreign exchange | 24 | 8 | |
Settlements | (81) | (53) | |
Ending | $518 | $452 | |
Level 3 - Liabilities | $518 | $452 | |
Total liabilities measured at fair value | $995 | $788 | |
Fair Value of Available for Sale Securities by Maturity | |||
2025 | 2024 | ||
Due in one year or less | $41 | $47 | |
Due after one year through three years | $48 | $44 | |
On December 31, 2025 the aggregate difference between the
cost and fair value of available-for-sale marketable securities was
nominal. Interest income on cash and cash equivalents, short-
term investments and marketable securities income was $121,
$139 and $75 in 2025, 2024 and 2023, which was recorded in
other income.
Our investments in available-for-sale marketable securities had a
minimum credit quality rating of A2 (Moody's), A (Standard &
Poor's) and A (Fitch). We do not plan to sell the investments, and
it is not more likely than not that we will be required to sell the
investments before recovery of their amortized cost basis, which
may be maturity.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 11, 2026 | Showing above |
| 2024 | Feb 12, 2025 | |
| 2023 | Feb 14, 2024 | |
| 2022 | Feb 10, 2023 | |
| 2021 | Feb 11, 2022 | |
| 2020 | Feb 11, 2021 | |
| 2019 | Feb 6, 2020 | |
| 2018 | Feb 7, 2019 | |
| 2017 | Feb 8, 2018 | |
| 2016 | Feb 9, 2017 | |
| 2015 | Feb 11, 2016 | |
About Fair Value Disclosures
Fair value disclosures classify all assets and liabilities measured at fair value into a three-level hierarchy: Level 1 (quoted market prices), Level 2 (observable inputs like yield curves), and Level 3 (unobservable inputs requiring management estimates). The proportion of Level 3 assets directly reflects how much of the balance sheet depends on internal models rather than market evidence.
Key signals: a growing Level 3 balance relative to total fair-value assets increases valuation uncertainty and earnings volatility risk. Watch for transfers between levels — assets moving from Level 2 to Level 3 often signal deteriorating market liquidity. Unrealized gains and losses on Level 3 positions flow through earnings or other comprehensive income, so large swings deserve scrutiny. For financial institutions, examine the sensitivity disclosures that show how Level 3 valuations change under alternative assumptions. Compare the fair value of debt against its carrying amount to gauge hidden leverage.